Research progress on microRNA in gout

Jing Xie; Cuixia He; Yue Su; Yuzhou Ding; Xingyu Zhu; Yuanyuan Xu; Jiaxiang Ding; Huan Zhou; Hongju Wang

doi:10.3389/fphar.2022.981799

Research progress on microRNA in gout

Front Pharmacol. 2022 Oct 20:13:981799. doi: 10.3389/fphar.2022.981799. eCollection 2022.

Authors

Jing Xie¹, Cuixia He^{1

2}, Yue Su^{1

3}, Yuzhou Ding¹, Xingyu Zhu^{1

2}, Yuanyuan Xu^{1

2}, Jiaxiang Ding^{1

3}, Huan Zhou^{1

2

3}, Hongju Wang¹

Affiliations

¹ Clinical Trials Center, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
² School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China.
³ School of Public Foundation, Bengbu Medical College, Bengbu, Anhui, China.

Abstract

Gout is a common form of arthritis caused by the deposition of sodium urate crystals in the joints and tissues around them. MicroRNAs (miRNAs) are noncoding RNAs that have been shown to be involved in regulating the pathogenesis of gout through multiple cellular signaling pathways, which may be potential targets for the treatment of gout. In this review, we systematically discuss the regulatory roles of related miRNAs in gout, which will provide help for the treatment of gout and miRNAs is expected to become a potential biomarker for gout diagnosis.

Keywords: biomarker; cellular signaling pathway; gout; microRNA; treatment.

Publication types

Review